

# ORCA - Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/99332/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Hayashi, Ryuhei, Ishikawa, Yuki, Katori, Ryousuke, Sasamoto, Yuzuru, Taniwaki, Yuki, Takayanagi, Hiroshi, Tsujikawa, Motokazu, Sekiguchi, Kiyotoshi, Quantock, Andrew J. and Nishida, Kohji 2017.
Coordinated generation of multiple ocular-like cell lineages and fabrication of functional corneal epithelial cell sheets from human iPS cells. Nature Protocols 12 (4), pp. 683-696. 10.1038/nprot.2017.007

Publishers page: http://dx.doi.org/10.1038/nprot.2017.007

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1	Editorial Summary: This protocol describes how to grow a functional and transplantable corneal
2	epithelium and how to generate ocular-like cell lineages resembling neuroectoderm, neural
3	crest, ocular surface ectoderm or surface ectoderm derived from human iPS cells.
4	
5	Co-ordinated generation of multiple ocular-like cell lineages and fabrication of
6	functional corneal epithelial cell sheets from human iPS cells
7	Ryuhei Hayashi <sup>1, 2*</sup> , Yuki Ishikawa <sup>2</sup> , Ryousuke Katori <sup>2</sup> , Yuzuru Sasamoto <sup>2</sup> , Yuki Taniwaki <sup>2</sup> ,
8	Hiroshi Takayanagi <sup>2</sup> , Motokazu Tsujikawa <sup>2</sup> , Kiyotoshi Sekiguchi <sup>3</sup> , Andrew J. Quantock <sup>4</sup> , &
9	Kohji Nishida <sup>2*</sup>
10	<sup>1</sup> Department of Stem Cells and Applied Medicine, Osaka University Graduate School of
11	Medicine, Suita, Osaka, 565-0871, Japan. <sup>2</sup> Department of Ophthalmology, Osaka University
12	Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. <sup>3</sup> Division of Matrixome
13	Research and Application, Institutes for Protein Research, Osaka University, Suita, Osaka,
14	565-0871, Japan. <sup>4</sup> Structural Biophysics Group, School of Optometry and Vision Sciences,
15	College of Biomedical and Life Sciences, Cardiff University, Cardiff, CF24 4HQ, Wales, UK.
16	*Co-corresponding authors: Ryuhei Hayashi (ryuhei.hayashi@ophthal.med.osaka-u.ac.jp) and
17	Kohji Nishida (knishida@ophthal.med.osaka-u.ac.jp)
18	

# 1 ABSTRACT

2	We describe a protocol for the generation of a functional and transplantable corneal epithelium
3	derived from human induced pluripotent stem (iPS) cells. In our experiments a proportion of
4	iPS cells spontaneously form circular colonies, each of which is comprised of four concentric
5	zones. Cells in these zones have different morphologies and immunostaining characteristics,
6	resembling neuroectoderm, neural crest, ocular surface ectoderm or surface ectoderm. We term
7	this two-dimensional (2D) colony a SEAM (a self-formed, ectodermal, autonomous, multi-
8	zone), and propose that cells within it have the potential to give rise to anlages of different
9	ocular lineages including retinal cells, lens cells, and ocular surface ectoderm. To investigate the
10	translational potential of the SEAM, cells within it that resembled ocular surface epithelia were
11	isolated by pipetting and sorted by FACS into a population of corneal epithelial-like progenitor
12	cells. These were then expanded and differentiated to form an epithelial layer, which expressed
13	K12 and PAX6 and which was able to recover function in an animal model of corneal epithelial
14	dysfunction after surgical transplantation. The whole protocol, encompassing human iPS cell
15	preparation, autonomous differentiation, purification and subsequent differentiation takes
16	between 100 and 120 days, and is of potential use to researchers with an interest in eye
17	development and/or ocular surface regeneration. We suggest that experience with human iPS
18	cell culture and sorting via FACS will be of benefit for researchers performing this protocol.
19	2

# 1 INTRODUCTION

2	Induced pluripotent stem (iPS) cells are highly influential in life sciences research, and the
3	fields of fundamental and translational eye research are no exceptions <sup>1,2</sup> . Noteworthy in this
4	regard are studies that have used embryonic stem (ES) cells and iPS cells to advance our
5	knowledge of ocular morphogenesis, and the potential of stem cell-derived tissue for surgical
6	use <sup>3-7</sup> . The front of the eye is formed by the cornea, a curved and clear collagen-rich tissue that
7	is overlaid by a specialised multi-layered epithelium that supports the tear-film. Research into
8	the corneal epithelium is active owing to the prevalence of blinding and difficult-to-treat ocular
9	surface injuries or diseases. At present, convincing methods for the production of corneal
10	epithelial stem cells and progenitor cells by direct differentiation from iPS cells, and the
11	subsequent expansion of these cells into functional epithelial tissues, are lacking. To try to
12	address this and to investigate the possible generation of multiple ocular cell lineages, we
13	recently reported the fabrication of a self-formed, ectodermal, autonomous, multi-zone (SEAM)
14	of ocular cells from human iPS cells <sup>8</sup> . The SEAM contains four concentric zones of cells, each
15	of which has the characteristics of a particular ocular cell lineage or lineages. From the cell zone
16	of the SEAM that most closely resembles the ocular surface epithelium we isolated and sorted
17	functional corneal epithelial stem/progenitor cells8. Here, we report a detailed protocol for
18	generating a SEAM from human iPS cells and the subsequent fabrication of functional corneal

2	
3	Development of the Protocol
4	Recent research with pluripotent stem cells in culture has identified a previously
5	underappreciated level of intrinsic cellular self-organization, and has provided evidence of
6	cupping of the neural retina when a three-dimensional (3D) culture system was used <sup>4</sup> . However,
7	this work provided no signs of ocular surface development. We have now developed a culture
8	technique that can partially mimic whole eye development encompassing all key ocular
9	component tissues. To achieve this, we adopt a 2D culture system and use laminin 511 E8-
10	fragment as a substrate for ocular cell growth. Various types of serum-free differentiation
11	medium were used to promote spontaneous eye-like differentiation of human iPS cells.
12	
13	Comparison with other methods
14	As mentioned, research using 3D culture techniques has successfully demonstrated spontaneous
15	retinal tissue formation from human iPS cells <sup>4</sup> . However, this approach has not led to the
16	generation of corneal or other anterior eye tissues. It has also been shown, by us and others, that
17	the use of a 2D-culture system with feeder cells or their conditioned medium (e.g. corneal

- limbal fibroblasts or PA6 mouse feeder cells) is able to induce corneal epithelial-like cells from
- iPS cells, but the purification of these cells was ultimately not achievable<sup>9,10</sup>. In essence, these

T	cells appeared to be "corneal epithelial-like cells" and, indeed, they expressed corneal epithelial
2	markers. But, ultimately, they did not undergo subsequent physiological development and
3	differentiation <sup>9-11</sup> . The protocol we describe here is distinct because it generates a range of
4	cellular anlages that have characteristics of several quite separate tissues in the eye. The culture
5	techniques do not require the use of feeder cells or FBS, and the iPS cell-derived corneal
6	epithelial stem and progenitor cells undergo purification by FACS using a combination of
7	antibodies. This approach confers a crucial advantage for future potential clinical applications
8	because the final product (i.e. the corneal epithelial cell sheets) will be devoid of non-corneal
9	iPS-derived epithelial cells and of cellular impurities that might originate from feeder cells.
10	
10 11	Limitations
10 11 12	<b>Limitations</b> In this series of experiments, it became apparent that different human iPS cell clones had
10 11 12 13	Limitations In this series of experiments, it became apparent that different human iPS cell clones had different propensities for differentiation. Indeed, some clones only infrequently formed a SEAM
10 11 12 13 14	Limitations         In this series of experiments, it became apparent that different human iPS cell clones had         different propensities for differentiation. Indeed, some clones only infrequently formed a SEAM         or resulted in the successful generation of a FACS-sorted corneal epithelial cell layer.
10 11 12 13 14 15	Limitations         In this series of experiments, it became apparent that different human iPS cell clones had         different propensities for differentiation. Indeed, some clones only infrequently formed a SEAM         or resulted in the successful generation of a FACS-sorted corneal epithelial cell layer.         Commercially available 201B7 and 454E2 iPS cell clones, along with clone 1383D2, provided
10 11 12 13 14 15 16	Limitations         In this series of experiments, it became apparent that different human iPS cell clones had         different propensities for differentiation. Indeed, some clones only infrequently formed a SEAM         or resulted in the successful generation of a FACS-sorted corneal epithelial cell layer.         Commercially available 201B7 and 454E2 iPS cell clones, along with clone 1383D2, provided         by the Center for iPS Cell Research and Applications (CiRA) at Kyoto University, displayed a
10 11 12 13 14 15 16 17	Limitations         In this series of experiments, it became apparent that different human iPS cell clones had         different propensities for differentiation. Indeed, some clones only infrequently formed a SEAM         or resulted in the successful generation of a FACS-sorted corneal epithelial cell layer.         Commercially available 201B7 and 454E2 iPS cell clones, along with clone 1383D2, provided         by the Center for iPS Cell Research and Applications (CiRA) at Kyoto University, displayed a         good differentiation potential. Clone 253G1, on the other hand, was found to be poor in terms of

 $\mathbf{5}$ 

1	different human iPS cell clones might be a consequence of dissimilarities in epigenetic status <sup>11-</sup>
2	<sup>13</sup> , but at this stage of our research it is too early to definitively identify a particular human iPS
3	cell clone(s) as best-suited for use in SEAM-formation and subsequent corneal differentiation.
4	Of course, this question could be resolved by optimizing the cultivation protocol for each
5	human iPS cell clone, but we have not undertaken this task. As such, and based on our
6	experience to date, it would seem sensible to recommend the use of clone 201B7, a frequently
7	used clone in the field of human iPS cell research <sup>14-16</sup> , for the experiments we describe. Finally,
8	we note that the protocol described here, especially in its latter parts, is targeted at inducing
9	corneal epithelial cells from the human iPS cell-derived SEAM. Effectively obtaining other cell
10	types such as neural crest cells or presumptive lens cells will likely require modifications to the
11	protocol.
12	
13	Applications
14	SEAMs generated by this protocol have potential use as in vitro cellular models for human eye
15	development. This will likely be of significant interest for research into human eye
16	development, particularly in the early stages, because most current information is based on
17	mouse or avian eye development. Moreover, because human iPS cells can be infinitely
18	amplified in culture a SEAM has the potential to act as a significant research resource for

human ocular cells, such as retinal cells or corneal epithelial cells, which are difficult to obtain
 otherwise.

3

#### 4 Experimental Design

This protocol is described in two parts: the first covers the human iPS cell culture and SEAM
formation (Steps 1–34; PART I); the second, the isolation of corneal epithelial cells from the
SEAM and their fabrication into functional and transplantable cell sheets (Steps 35–59; PART
II) (Fig.1).

10	PART I: Human iPS cell culture and SEAM formation (Steps 1–34) Human iPS cells to be
11	used for SEAM-formation and subsequent corneal epithelial differentiation were maintained on
12	Laminin-511 E8 fragment (LN511E8)-coated culture dishes in serum-free medium (StemFit <sup>TM</sup>
13	medium) for a minimum of three to four cell passages before initiating differentiation <sup>15,17</sup> (Fig.
14	2). The initial seeding density typically, we use 1500-4500 cells/6-well plate is an important
15	factor for the differentiation propensity. For example, at higher cell densities (e.g. 4500-6000
16	cells/6-well plate) the likelihood of corneal epithelial differentiation is enhanced. Seeding at
17	lower cell densities, (e.g. 1000-2000 cells/6-well plate), on the other hand, has the effect of
18	encouraging neural crest differentiation.

2	After the initial cell passaging, cultivation was continued in specific growth factor-free medium
3	(Differentiation medium; DM), whilst still on LN511E8, until the formation of a SEAM (Fig.
4	3A). As we reported recently <sup>8</sup> , a typical SEAM contains neuronal cells in the innermost zone
5	(zone 1), retina-like and neural crest-like cells in the adjacent radial zone (zone 2), ocular
6	surface ectoderm-like cells in the next zone outwardly (zone 3), lens-like cells in zones 2 and 3,
7	and non-ocular surface epithelial-like cells in the outermost zone (zone 4) (Fig. 3B).
8	After approximately four weeks of differentiation culture, we examined each zonal cell
9	population in the SEAM via immunofluorescence staining (Box 1). To verify the existence of
10	ocular cell lineages in each zone, the following antibody combinations were used and are
11	recommended: a PAX6/p63-double-positive phenotype for ocular surface ectoderm (an anlage
12	of the corneal epithelium) <sup>8,18,19</sup> ; TUBB3 and p63 for neuronal/epithelial cells <sup>20-22</sup> ; CHX10 and
13	MITF for neural-retina/retinal pigment epithelium (RPE) <sup>8,23</sup> ; SOX10 and p75 for neural crest
14	cells <sup>8,24</sup> ; and PAX6/ $\alpha$ -crystallin for lens cells <sup>25,26</sup> (Fig. 3B, Table 1).
15	
16	At the four-week timepoint we further studied cells in zone 3, i.e. those with characteristics of

18 the SEAM was further cultivated in corneal differentiation medium (CDM) containing growth

the ocular surface ectoderm, anlages of corneal epithelial stem and progenitor cells. To do this

1	factors and the ROCK inhibitor, Y-27632, for an additional four weeks. Three weeks into this
2	CDM culture period, (i.e. after seven weeks total culture time) we remove zone 1 and 2 cells
3	from the SEAM by manual pipetting, as is described later. During this second culture period,
4	immature ocular surface ectodermal cells proliferate and gradually differentiate into what will
5	later become functional corneal epithelial stem/progenitor cells. (As an alternative option for
6	encouraging retinal cell differentiation, we suggest a direct switch to corneal epithelial medium
7	(CEM), rather than CDM after the initial four week differentiation in DM).
8	
9	PART II: Isolation of corneal epithelial cells from the SEAM and their fabrication into
10	functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like
10 11	<b>functional and transplantable cell sheets (Steps 35–59).</b> As mentioned, corneal epithelial-like stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with
10 11 12	functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with characteristics of other ocular cell lineages (i.e. retinal cells, lens cells, or neuronal cells) are
10 11 12 13	functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with characteristics of other ocular cell lineages (i.e. retinal cells, lens cells, or neuronal cells) are generated in other zones of the same SEAM in the same culture dish (Fig. 1, 3B). To enrich and
10 11 12 13 14	functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with characteristics of other ocular cell lineages (i.e. retinal cells, lens cells, or neuronal cells) are generated in other zones of the same SEAM in the same culture dish (Fig. 1, 3B). To enrich and purify corneal epithelial-like cells, we remove these non-epithelial cellular zones from the
10 11 12 13 14 15	functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with characteristics of other ocular cell lineages (i.e. retinal cells, lens cells, or neuronal cells) are generated in other zones of the same SEAM in the same culture dish (Fig. 1, 3B). To enrich and purify corneal epithelial-like cells, we remove these non-epithelial cellular zones from the SEAM by manual pipetting (Fig. 4A). This can be carried out at around seven weeks of
10 11 12 13 14 15 16	functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with characteristics of other ocular cell lineages (i.e. retinal cells, lens cells, or neuronal cells) are generated in other zones of the same SEAM in the same culture dish (Fig. 1, 3B). To enrich and purify corneal epithelial-like cells, we remove these non-epithelial cellular zones from the SEAM by manual pipetting (Fig. 4A). This can be carried out at around seven weeks of differentiation, i.e. three weeks into the four-week CDM culture period. As described later, the
<ol> <li>10</li> <li>11</li> <li>12</li> <li>13</li> <li>14</li> <li>15</li> <li>16</li> <li>17</li> </ol>	functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with characteristics of other ocular cell lineages (i.e. retinal cells, lens cells, or neuronal cells) are generated in other zones of the same SEAM in the same culture dish (Fig. 1, 3B). To enrich and purify corneal epithelial-like cells, we remove these non-epithelial cellular zones from the SEAM by manual pipetting (Fig. 4A). This can be carried out at around seven weeks of differentiation, i.e. three weeks into the four-week CDM culture period. As described later, the pipetting can selectively remove neuronal-like cells from zones 1 and 2 of the SEAM without

1	pipetting away zone 1-2 cells, those remaining are further differentiated for an additional week
2	in CDM, so that a total of four weeks in CDM is achieved. Following this, i.e. at the eight-week
3	timepoint, the culture medium is switched to CEM (Fig. 4B) and cultivation is continued for a
4	further four weeks. Thus, the recommended culture time is 12 weeks in total, although this can
5	be reduced to 10-weeks by performing an abridged two-week CEM cultivation. This, however,
6	carries the risk of lessening the efficiency of corneal differentiation, which becomes more stable
7	after 12 weeks. (The maximum recommended culture time, depending on the logistics of the
8	experiments, is 16 weeks, which can be achieved by extending the final CEM cultivation period
9	to eight weeks). At the recommended 12-week timepoint FACS was performed using anti-
10	ITGB4, SSEA-4, and TRA-1-60 antibodies to isolate corneal epithelial stem/progenitor cells
11	(Fig. 4C). TRA-1-60, a pluripotent stem cell marker, was used to remove undifferentiated iPS
12	cells <sup>14,27</sup> , ITGB4 was used to select basal cells of the stratified epithelium, rich in epithelial
13	stem/progenitor cells <sup>8,28,29</sup> , whilst SSEA-4 was employed as it is expressed in corneal epithelial
14	cells as well as in a significant proportion of stem and progenitor cells in the corneal epithelial
15	stem cell niche at the edge of the cornea at the limbus of the $eye^{8,30}$ . This approach enabled the
16	high-purity isolation of corneal epithelial stem/progenitor cells consisting of TRA-1-60 <sup>-</sup>
17	/ITGB4 <sup>+</sup> /SSEA-4 <sup>+</sup> cells.

1	After sorting in this way, the FACS-isolated corneal stem/epithelial progenitor cells were
2	allowed to proliferate and form epithelial colonies on LN511E8-coated dishes in a feeder-less
3	culture system. After reaching confluence, cells became stratified and had formed a multi-
4	layered structure. To conduct cell-sheet transplantation in an animal model of corneal epithelial
5	injury, we harvested cell sheets at this juncture (i.e. after two-to-three weeks in culture). Sheets
6	were recoverable as intact cellular constructs, similar to those we have used in previous corneal
7	epithelial transplantation investigations <sup>31</sup> . Additionally, longer-term cultivation (up to 10 weeks)
8	of the sorted cells was conducted to promote cellular stratification and maturation, after which
9	we performed immunofluorescence microscopy to examine how patterns of protein expression
10	compared to those of normal cultivated human corneal limbal epithelium (Box 2). We
11	recommend immunofluorescence staining using the corneal epithelial-specific markers, K3,
12	K12, PAX6, p63, MUC1 and MUC16 (Fig. 5).
13	
14	MATERIALS
17	
15	Human iPS cell (201B7; RIKEN Bio Resource Center, #HPS0063)
16	Caution: All work with human iPS cells must be carried out in accordance with all relevant
17	institutional and governmental regulations, applicable in the investigator's home laboratory and
18	country. In our case, the experiments were approved by the Recombinant DNA Committees of
	11

1	Osaka University and were performed according to our institutional guidelines.
2	Critical: Human iPS cells should be routinely verified by microscopic observation. They should
3	exist as circular colonies composed of uniformly packed cells that exhibit immunostaining for
4	pluripotent stem cell markers, TRA-1-60 and SSEA-4.
5	Caution: The 201B7 human iPS cell line was tested as Mycoplasma negative by the provider
6	and by us. Human iPS cells should be regularly tested for Mycoplasma contamination by an
7	appropriate method (e.g., we used a PCR-based method employing the e-Myco <sup>TM</sup> Mycoplasma
8	PCR Detection Kit; iNtRON Biotechnology, # 25235).
9	PE-conjugated CD104 (ITGB4) (58BX4; Bio Legend, #327808)
10	PE-conjugated isotype control IgG (MOPC-173; BioLegend, #400214)
11	FITC-conjugated SSEA-4 (MC-813-70; BioLegend, #330410)
12	FITC-conjugated isotype control IgG (MG3-35; BioLegend, #401317)
13	Alexa647-conjugated TRA-1-60 (TRA-1-60-R; BioLegend, #330606)
14	Alexa647-conjugated isotype control IgM (MM-30; BioLegend, #401618)
15	Anti-PAX6 antibody (PRB-278P; BioLegend, #901301)
16	Anti-PAX6 antibody (AD2.35; Santa Cruz Biotechnology, #sc-53108)
17	Anti-p63 antibody (4A4; Santa Cruz Biotechnology, #sc-8431)
18	Anti-CHX10 antibody (N-18; Santa Cruz Biotechnology, #sc-21690)

1	Anti-MITF	antibody (	C5; Exalpha	Biologicals,	#X1405M)
		<i>.</i> .	/ I	0 /	

2	Anti-TUBB3 antibody (T2200; Sigma-Aldrich	, #T2200)
---	---	-----------

- 3 Anti-SOX10 antibody (N-20; Santa Cruz Biotechnology, #sc-17342)
- 4 Anti-p75 antibody (ME20.4; Advanced Targeting Systems, #AB-N07)
- 5 Anti-α-Crystallin antibody (SPA-224; Stressgen Biotechnologies, #SPA-224)
- 6 Anti-K12 antibody (N-16; Santa Cruz Biotechnology, #sc-17098)
- 7 Anti-K3/76 antibody (AE5; PROGEN Biotechnik, #61807)
- 8 Anti-MUC1 antibody (M4H2; Abcam, #ab10120)
- 9 Anti-MUC16 antibody (OV185:1; Abcam, #ab697)
- 10 Alexa Fluor 488 donkey anti-Rabbit IgG (H+L) (Life Technologies, #A21206)
- 11 Alexa Fluor 594 donkey anti-Rabbit IgG (H+L) (Life Technologies, #A21207)
- 12 Alexa Fluor 568 donkey anti-Goat IgG (H+L) (Life Technologies, #A11057)
- 13 Alexa Fluor 488 donkey anti-Mouse IgG (H+L) (Life Technologies, #A21202)
- 14 Alexa Fluor 568 donkey anti-Mouse IgG (H+L) (Life Technologies, #A10037)
- 15 4% (wt/vol) Paraformaldehyde phosphate buffer solution (PFA) (Wako, #163-20145)
- 16 Cellstain<sup>®</sup> Hoechst 33342 Solution (Wako, #346-07951)
- 17 Triton X-100 (SIGMA, #T8787-100ML)
- 18 Normal donkey serum (Jackson ImmunoResearch, #017-000-121)

- 1 TBS powder (TakaraBio, #T903)
- 2 StemFit<sup>™</sup> medium (Ajinomoto, #AK02 or AK03)
- 3 Accutase<sup>TM</sup> (Life Technologies, #A11105-01)
- 4 TrypLE<sup>TM</sup> Select (Life Technologies, #12563-029)
- 5 0.5 mM EDTA solution (Nacalai tesque, #13567-84)
- 6 Trypan Blue Stain 0.4% (Thermo Fisher Scientific, #T10282)
- 7 KGF (R&D, #251-KG or Wako, #112-00813)
- 8 Y-27632 (Wako, #034-24024)
- 9 B-27 supplement (Life Technologies, #17504-044)
- 10 LN511E8 fragment (i-Matrix-511; Nippi, #892011)
- 11 GMEM (Life Technologies, #11710-035)
- 12 Penicillin-Streptomycin solution (Life Technologies, #15140-122)
- 13 Non-essential amino acids (Life Technologies, #11140-050)
- 14 Sodium pyruvate (Life Technologies, #11360-070)
- 15 Knockout serum replacement (KSR) (Life Technologies, #10828-028)
- 16 2-mercaptoethanol (2-ME) (Life Technologies, #21985-023)
- 17 Caution: 2-ME is toxic and flammable. Wear gloves and handled it carefully.
- 18 Monothioglycerol (replacement for 2-ME) (Wako, #195-15791)

- 1 CnT-PR [w/o; EGF and FGF2] (CELLnTEC, #CnT-PR-EF)
- 2 DMEM/F-12 [1:1] (Life Technologies, #11320-033)
- 3 DMEM without glutamine and Nutrient Mixture F-12 Ham (3:1) (Life Technologies, #10313-
- 4 021, #11765-054)
- 5 Hydrocortisone succinate (Wako, #080-05581)
- 6 3,3',5-Triiodo-L-thyronine sodium salt (MP Biomedicals, #194585)
- 7 Cholera toxin (List Biological Laboratory, #100B)
- 8 Caution: Cholera toxin is potentially harmful. Wear gloves and handle it carefully in a biosafety
- 9 cabinet.
- 10 Bovine transferrin HOLO form (Life Technologies, #11107-018)
- 11 L-glutamine (Life Technologies, #25030-081)
- 12 Insulin transferrin selenium solution (Life Technologies, #41400-045)
- 13 FBS (Japan Bio Serum, #15-001-JBS or Life Technologies, #12483-020)
- 14 STEM-CELLBANKER (TakaraBio, #CB046)
- 15 DPBS, no calcium, no magnesium (Life Technologies, #14190-144)

- 17 Equipment
- 18 Cell sorter (BD Biosciences, FACSAriaII)

- 1 CO<sub>2</sub> Incubator (Panasonic, #MCO-20AIC)
- 2 Bio-clean bench (Panasonic, #MCV-B131F)
- 3 Bio-safety cabinet (ESCO, #JA2-4A7)
- 4 Ultra-low freezer (Panasonic, #MDF-U33V)
- 5 Ultra-low freezer (Panasonic, #MDF-C2156VAN)
- 6 Fluorescent microscope (Carl Zeiss, Axio Observer. D1)
- 7 Fluorescent microscope (Thermo Fisher Scientific, EVOS®)
- 8 Stereomicroscope (Olympus, #SZ61)
- 9 Centrifuge machine (TOMY, #LC-230)
- 10 Culture plate 6-well, 12-well (Corning, #353046, #353043)
- 11 Culture insert 12-well (FALCON, #353180)
- 12 UpCell<sup>®</sup> 6-well plate (CellSeed, #CS3004)
- 13 STEMFULL<sup>TM</sup> tube (Sumitomo Bakelite, #MS-90150)
- 14 Cell Strainer (40 µm) (Corning, #352340)
- 15 Automated cell counter (Thermo Fisher Scientific, Countess®)
- 16 PVDF membrane filter (Millipore, #SVWG04700)
- 17 Cell Scraper (Sumitomo Bakelite, #MS-93100)
- 18 Falcon 50-mL polypropylene conical tube (FALCON, #352070)

1 Falcon 15-mL polypropylene conical tube (FACLON, #352096)

2	PermaFluor <sup>TM</sup> Aqueous Mounting Medium (Thermo Fisher Scientific, # TA-030-FM).
3	
4	REAGENT SET-UP
5	<b>Differentiation medium (DM)</b> GMEM supplemented with 10% (vol/vol) knockout serum
6	replacement (KSR), 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 2 mM L-
7	glutamine, 1% (vol/vol) penicillin-streptomycin solution, and 55 $\mu$ M 2-mercaptoethanol (2-ME)
8	or monothioglycerol (a replacement for 2-ME) <sup>32</sup> .
9	The medium should be stored at 4 °C and used within two weeks.
10	Caution: 2-ME is toxic and flammable. Wear gloves and handle it carefully.
11	KGF frozen stock Dissolve 1.0 mg of KGF in 50 mL of PBS containing 0.1% (wt/vol) human
12	serum albumin and store at 50-100 $\mu L/tube$ (20 $\mu g/mL)$ at -80°C or -30°C for up to three
13	months.
14	<b>Y-27632 frozen stock</b> Dissolve 25 mg of Y-27632 in 7.4 mL of PBS and store at 50 $\mu$ L/tube (10
15	mM) at -30°C or -80°C for up to six months.
16	Corneal differentiation medium (CDM) Prepare DM and CnT-PR [w/o EGF and FGF2] (1:1)
17	containing 10-20 ng/mL KGF, 10 $\mu M$ Y-27632, and 1% (vol/vol) penicillin-streptomycin
18	solution. Add KGF and Y-27632 to the basal medium of the CDM (w/o KGF and Y-27632)

1 before use. The basal medium should be stored at 4  $^\circ$ C and used within two weeks.

2	Corneal epithelium maintenance medium (CEM) Prepare DMEM/F-12 [1:1] containing 2%
3	(vol/vol) B-27 supplement, 10-20 ng/mL KGF, 10 $\mu$ M Y-27632, and 1% (vol/vol) penicillin-
4	streptomycin solution. Add B-27 supplement, KGF, and Y-27632 to the basal medium of CEM
5	(w/o B-27, KGF, and Y-27632) before use. The basal medium should be stored at $4^{\circ}$ C and used
6	within two weeks.
7	KCM medium Prepare DMEM without glutamine and Nutrient Mixture F-12 Ham (3:1)
8	supplemented with 5% (vol/vol) FBS, 0.4 $\mu$ g/mL hydrocortisone succinate, 2 nM 3,3',5-triiodo-
9	L-thyronine sodium salt, 1 nM cholera toxin, 2.25 $\mu$ g/mL bovine transferrin HOLO form, 2 mM
10	L-glutamine, 0.5% (vol/vol) insulin transferrin selenium solution, and 1% (vol/vol) penicillin-
11	streptomycin solution. The medium should be stored at 4 °C and used within three weeks.
12	Corneal epithelium-maturation medium (CMM) Prepare KCM medium containing 10-20
13	ng/mL KGF and 10 $\mu$ M Y-27632. Add KGF and Y-27632 to the KCM before use. The basal
14	medium (KCM medium) should be stored at 4°C and used within three weeks.
15	
16	PROCEDURE
17	Human iPS cell maintenance and subculture: <i>Plate coating</i> TIMING ~3 h
18	CRITICAL The use of an appropriate human iPS cell clone is important to achieve successful

1	ocular surface epithelial cell differentiation. As discussed earlier, we found clone 201B7 to be
2	suitable for the protocol described here, however other clones conceivably could be used with
3	appropriate modifications to the protocol.
4	1. Coat new 6-well culture plates with LN511E8 (i-Matrix) at 0.5 $\mu g/cm^2$ in 1.5 mL of PBS by
5	incubation at 37°C for 2 hr.
6	2. Add 0.7 mL of StemFit <sup>TM</sup> medium to the culture plates.
7	3. Remove the mixed solution and immediately add 1.5 mL of StemFit <sup>TM</sup> medium containing 10
8	μM Y-27632.
9	Critical step: Do not allow the surface of the culture plates to dry. Add StemFit <sup>TM</sup> medium
10	immediately after the removal of the coating solution.
11	4. Incubate plates at 37°C in 5% CO <sub>2</sub> for around 15 min whilst preparing human iPS cells, as
12	described in steps 5-12.
13	Human iPS cell maintenance and subculture: Human iPS cell seeding from frozen cell stock
14	TIMING 7 d
15	5. Add 5 mL of StemFit <sup>TM</sup> medium to a 15-mL conical tube.
16	6. Take a frozen stock of $2 \times 10^5$ of human iPS cells, preserved in 0.2 mL STEM-
17	CELLBANKER from a liquid nitrogen tank or an ultra-deep freezer (-150°C) and thaw in a
18	water bath at 37°C.

1	Critical step: Do not leave the frozen cells in the water bath for too long, as this could cause cell
2	death.
3	7. Immediately after thawing, transfer the cell suspension into 5 mL of StemFit <sup>TM</sup> medium in the
4	15-mL conical tube.
5	Critical step: Do not perform manual pipetting more than twice, to reduce the risk of cell
6	damage.
7	8. Centrifuge the cells at $160 \times g$ for 5 min at room temperature (20-28°C).
8	9. Remove the supernatant.
9	10. Add 0.5 mL of StemFit <sup>TM</sup> medium and pipette the cells.
10	11. Count the collected cells using a Countess® Machine immediately after staining with Trypan
11	blue (settings for Countess <sup>®</sup> : sensitivity = 5, minimum size = 8, maximum size = 30, circularity
12	= 75).
13	12. Seed cells on the LN511E8 coated 6-well culture plates (from Step 4) at 65,000 cells/well.
14	Critical step: Spread the cells evenly after seeding.
15	13. Incubate the plates overnight at 37°C in 5% CO <sub>2</sub> .
16	14. The next day, replace the medium with fresh StemFit <sup>TM</sup> medium without Y-27632 and
17	incubate at 37°C in 5% CO <sub>2</sub> up to day 7. The medium should be changed every two days.
18	TROUBLESHOOTING

#### 1 Human iPS cell maintenance and subculture: Cell passaging TIMING at least 7-21 d

- 2 15. Prepare LN511E8-coated 6-well culture plates as described in Steps 1-4.
- 3 16. Remove the culture medium from human iPS cells.
- 4 17. Wash the cells once with 1 mL of PBS.
- 5 18. Add 300 μL of dissociation solution (50% (vol/vol) TrypLE Select and 50% (vol/vol) 0.5
- 6 mM EDTA solution) and incubate for 4-5 min at 37°C.
- 7 19. Remove the dissociation solution.
- 8 Critical step: Perform this step carefully because the human iPS cells are still attached to the
- 9 culture plates at this point.
- 10 20. Wash the cells once with 2 mL of PBS and then add 1 mL of StemFit<sup>TM</sup> medium containing

11 10 µM Y-27632.

- 12 21. Detach the cells from the culture plates mechanically using a Cell Scraper.
- 13 22. Pipette the cells about 10 times with a 200- or 1000-µL micropipette and transfer the
- 14 dissociated ones to a 1.5-mL tube.
- 15 23. Count the collected human iPS cells using a Countess<sup>®</sup> Machine immediately after staining
- 16 with Trypan blue (settings for Countess<sup>®</sup>: sensitivity = 5, minimum size = 8, maximum size =
- 17 30, circularity = 75).
- 18 24. Seed the cells on LN511E8 coated 6-well culture plates (from Step 15) at 13,000 cells/well.

1 Critical step: Spread out the cells evenly after seeding.

2	25. Incubate overnight at 37°C in 5% CO <sub>2</sub> .
3	26. The next day, replace the medium with fresh StemFit <sup>TM</sup> medium without Y-27632 and
4	incubate at $37^{\circ}$ C in 5% CO <sub>2</sub> up to day seven. The medium should be changed every two days.
5	CRITICAL STEP : In modified protocols iPS cells might have been maintained in conditions
6	other than those described above (for example, using co-culture with MEF feeder layers or in
7	other feeder-less culture systems). If this is the case, after the removal of the feeder cells the
8	dissociated iPS cells should be seeded in the StemFit <sup>TM</sup> /LN511E8 culture system at 13,000
9	cells/well and passaged at least three to four times to adapt to the changed conditions.
10	CRITICAL STEP: We used human iPS cells before passage 40 for our differentiation experiments,
11	but we have no definitive data regarding the influence of cell passage number on iPS cells and
12	their differentiation.
13	Differentiation culture: Preparing human iPS cells for differentiation culture TIMING 10 d
14	27. Coat a 6- or 12-well culture plate with LN511E8 at 0.5 $\mu$ g/cm <sup>2</sup> as described in Steps 1-4.
15	28. Harvest human iPS cells by the same method used for their passaging in steps 15-26.
16	29. Seed the dissociated cells on 6-well plates at 1500-6000 cells/well, or on 12-well plates at
17	500-2000 cells/well in 1.5 mL (6-well plate) or 0.6-mL (12-well plate) of StemFit <sup>TM</sup> medium
18	containing 10 µM Y-27632.

1	Critical step: The initial seeding density is important. To generate SEAMs, a relatively low cell
2	density (e.g. 1500-4500 cells/6-well plate) is recommended. This will help to avoid the fusion of
3	colonies. We found that to successfully generate corneal epithelial progenitor cells a relatively
4	high cell density (e.g. 4500-6000 cells/6-well plate) is required. The high seeding density,
5	however, is accompanied by the associated risk that colonies might fuse, which makes it
6	difficult to obtain regular concentric multiple cellular zones within all SEAMs. For neural crest
7	induction in SEAM zone-2, a lower cell density (e.g. 1000-2000 cells/6-well plate) is suitable.
8	30. Incubate overnight at $37^{\circ}$ C in 5 % CO <sub>2</sub> .
9	31. The next day, 24 hrs after seeding, replace the medium with fresh StemFit <sup>TM</sup> medium
10	without Y-27632.
11	32. Incubate the plates at 37°C in 5% CO <sub>2</sub> (for 10 days in total). Change the medium every two
12	days before day 7 and every day thereafter.
13	Differentiation culture: Ocular cell differentiation culture (Day 0-) TIMING 4 w
14	33. After 10 days in culture in StemFit <sup>TM</sup> medium, replace it with DM and use volumes of 2 mL
15	(in a 6-well plate) or 1 mL (in a 12-well plate) (Day 0).
16	34. Incubate at $37^{\circ}$ C in 5% CO <sub>2</sub> for 4 weeks, changing the medium every 2-3 days to achieve
17	three changes per week.
18	At 3-4 weeks, approximately 60-70% of human iPS cell colonies should appear as circular

1	colonies comprised of 3-4 concentric zones <sup>8</sup> . As mentioned previously, this type of colony has
2	been termed a "SEAM" a self-formed ectodermal autonomous multi-zone <sup>8</sup> . To verify the
3	existence of the ocular cell lineages in each zone, immunostaining for ocular cell makers is
4	useful (BOX 1). Within a SEAM cells in the third zone from the center have characteristics of
5	ocular surface ectodermal cells (PAX6/p63-double-positive phenotype) and the ability to
6	differentiate into functional corneal epithelial cells.
7	TROUBLESHOOTING
8	Differentiation culture: CDM culture (Day 28-) TIMING 4 w
9	35. After 4 weeks of incubation in DM, replace the medium with either 2 mL (in a 6-well plate)
10	or 1 mL (in a 12-well plate) of CDM.
11	36. Incubate the plates for an additional 4 weeks at 37°C in 5% CO <sub>2</sub> (8 weeks culture in total).
12	The medium should be changed every 2-3 days (around 3 times per week).
13	Optional: To encourage retinal cell differentiation, change the medium to CEM, rather than
14	CDM, at day 28. After incubation in CEM for an additional 2 to 3 weeks (i.e. 6 to 7 weeks of
15	culture in total) pigmented retinal pigment epithelium (RPE)-type cells can be observed in zone
16	2 of the SEAM.
17	Differentiation culture: Manual pipetting to remove non-epithelial cells (Day 49) TIMING
18	1d

1	37. At around three weeks of incubation in CDM (i.e. after seven weeks of culture in total)
2	perform manual pipetting using a PIPETMAN <sup>TM</sup> (1000 $\mu$ L or 200 $\mu$ L) on a clean bench to
3	remove non-epithelial like cells (e.g. neuronal-type cells, retinal-type cells, and/or lens-type
4	cells) from zones 1 and 2 of the SEAM. Cells in zones 1 and 2 of the SEAM adhere to the
5	culture plates less strongly than cells in zones 3 and 4. Because of this, manual pipetting can be
6	used to rinse away zone 1-2 cells from the SEAM, whilst leaving zone 3-4 cells intact. To do
7	this, simply aspirate some CDM medium from the culture dish and flush it over the SEAM. This
8	can either be carried out using 150-200 $\mu l$ of medium and a 200 $\mu l$ PIPETMANTM or 500-800
9	$\mu$ l of medium and a 1000 $\mu$ l PIPETMANTM. Typically, one wash is sufficient using the larger
10	pipette, whereas two or three repeats tend to be needed using the smaller one. In both cases, the
11	pipette tip is larger than the SEAM. Depending on seeding density and closeness of the SEAMs,
12	the larger pipette can often treat several SEAMs in one action. The procedure seems to work
13	best if the pipette is angled away from 90° to the surface of the SEAM.
14	CRITICAL STEP: Pipetting causes the yield of corneal epithelial-type cells for subsequent cell
15	sorting to be higher than it would have been had manual pipetting not been carried out.
16	CRITICAL STEP: Caution: Some practice is required here. Do not perform the pipetting too
17	vigorously; otherwise, it will detach not only zone 1 and 2 cells, but those in zones 3 and 4 as
18	well. Also, take care that the pipette tip does not actually touch the SEAM.

1	<b>CRITICAL STEP:</b>	A stereomicroscop	pe is useful,	but not essential,	for p	performing	this step	p.
			· · · · · · · · · · · · · · · · · · ·			- U		

- $\mathbf{2}$
- 3 38. After pipetting, discard the medium containing the detached cells, and add fresh CDM to the
  4 culture plate.
- 5 39. Incubate the plates for one additional week in CDM for eight weeks of culture in total.

#### 6 Differentiation culture: CEM culture (Day 56-) TIMING at least 2-4 w

- 7 40. After CDM culture for four weeks (i.e. eight weeks overall), change the medium to 2 mL (in
- 8 a 6-well plate) or 1 mL (in a 12-well plate) of CEM.
- 9 41. Incubate the plates for between two weeks (i.e. 10 weeks in total) and eight weeks (i.e. 16
- 10 weeks in total) at 37°C in 5 % CO<sub>2</sub>. As before, the medium should be changed every 2-3 days
- 11 (i.e. three times per week). In most case, 12 weeks is suitable for subsequent cell sorting.

#### 12 FACS for isolating corneal epithelial stem/progenitor cells (Day 70-): Cell staining with

- 13 antibodies. TIMING at least 3 h
- 14 42. After CEM culture, wash the differentiated human iPS cells once with PBS.
- 15 43. Add 1mL (in a 12-well plate) or 2 mL (in a 6-well plate) of Accutase<sup>TM</sup> and incubate for 45

16 min at 37°C.

- 17 44. Perform pipetting several times using a PIPETMAN<sup>TM</sup> (1000  $\mu$ L) to dissociate the cells and
- 18 incubate, once more, for 15 min at 37°C.

1	45. Collect and re-suspend the dissociated cells in ice-cold KCM medium in a STEMFULL <sup><math>TM</math></sup>
2	15-mL tube.
3	46. Filter the cells using a Cell Strainer (40 $\mu$ m) and count the cells.
4	47. Centrifuge at $280 \times g$ for 8 min at room temperature.
5	48. Aspirate the supernatant and re-suspend the cells in ice-cold KCM containing FITC-
6	conjugated SSEA-4 (MC813-70), PE-conjugated CD104 (ITGB4; 58BX4), and Alexa647-
7	conjugated TRA-1-60 (TRA-1-60R) antibodies. For isotype control, stain cells with FITC-, PE-,
8	or Alexa647-conjugated non-specific isotype antibodies (for SSEA-4, ITGB4 and TRA-1-60,
9	respectively). For colour compensation on flow cytometry, to be performed according to
10	manufacturer's protocols, stain cells with each single antibody against SSEA-4, ITGB4 and
11	TRA-1-60. The cell density should be less than $1 \times 10^7$ cells/mL.
12	49. Incubate the cells for 1 hr at 4°C, agitating every 20 min.
13	50. Wash the cells twice with PBS.
14	51. Re-suspend the cells in PBS by filtration using a Cell Strainer (40 $\mu$ m).
15	TROUBLESHOOTING
16	FACS for isolating corneal epithelial stem/progenitor cells: Cell sorting TIMING at least
17	2.5 h
18	52. Set up the FACSAriaII machine according to manufacturer's protocol.

 $\mathbf{27}$ 

1	53. Subject isotype antibody stained samples and single colour-stained samples sequentially to
2	the FACSAriaII and acquire the data.
3	54. Perform compensation between the detectors for FITC, PE, and Alexa647 using each of the
4	single-stained cells according to manufacturer's protocols applicable to FACSAriaII.
5	CRTICAL STEP: A positive region for each antibody staining needs to be defined, and this is
6	defined as a region that contains almost no cells (e.g. less than 0.3%) stained with the
7	corresponding isotype control antibody.
8	55. Analyze the triple colour-stained cells according to manufacturer's protocols of FACSAriaII.
9	Briefly, a Alexa647 negative region (TRA-1-60 negative cell population) is selected, after which
10	the population is analyzed by FITC (SSEA-4) and PE (ITGB4) using dot plot.
11	TROUBLESHOOTING
12	56. Sort the SSEA-4 <sup>+</sup> /ITGB4 <sup>+</sup> /TRA-1-60 <sup>-</sup> population (i.e. the human iPS cell-derived corneal
13	epithelial cell (human iCEC) fraction) to 8 mL of KCM in a STEMFULL <sup>TM</sup> 15-mL tube.
14	Typically, in TRA-1-60 negative cells, 5-20% of the cells are identified as the human iCEC
15	fraction.
16	TROUBLESHOOTING
17	57. Collect human iCECs by centrifugation at $280 \times g$ for 8 min at room temperature.

18 58. Re-suspend the cells in CEM on ice.

## 1 TROUBLESHOOTING

2	Fabrication of human iCEC sheet (Day 70)
3	59. At this stage, two options exist for the fabrication of human induced corneal epithelial cell
4	(iCEC) sheets. Follow Option A for cultivation on a temperature-responsive culture plate or
5	Option B for longer-term culture on a cell culture insert.
6	Option A. Cultivation on a temperature-responsive culture plate and cell harvest. TIMING
7	10-22 d
8	i. Coat a 6-well UpCell <sup>®</sup> plate with LN511E8 at 0.25-0.5 $\mu g/cm^2$ and incubate at 37°C for 60
9	min.
10	ii. Seed FACS-sorted SSEA-4 <sup>+</sup> /ITGB4 <sup>+</sup> /TRA-1-60 <sup>-</sup> cells (i.e. human iCECs) on the 6-well
11	UpCell <sup>®</sup> plate at 1.5-6.0 × $10^5$ cells/well in CEM.
12	iii. Incubate the plates at 37°C in 5% CO <sub>2</sub> for 5-12 days until cells reach 100% confluence.
13	Change the medium every two days.
14	iv. After cells reach confluence, replace the medium with CMM.
15	v. Incubate the cells in CMM for a further 3-10 days at $37^{\circ}$ C in 5% CO <sub>2</sub> to allow stratification
16	We find that the procedure works as long as the CMM incubation is within the 3-10 day
17	window.
18	Change the medium every two days.

1 VI. Incubate the Opcen plate at 20 C 101 50 Init	1	vi. Incubate the	UpCell <sup>®</sup>	plate at 20°C for 30 min
--	---	------------------	---------------------	--------------------------

- 3 cell sheet to act as a carrier as described in detail in reference 33.
- 4 viii. Harvest the cell sheet using fine surgical tweezers under a stereomicroscope. Specifically,
- 5 detach the peripheral part of the cell sheet from the dish and place it on the membrane.
- 6 Subsequent to this, it is straightforward to harvest the cell sheet by simply lifting the membrane
- 7 with the cell sheet using surgical tweezers.

#### 8 TROUBLESHOOTING

- 9 Option B. Insert culture (for longer-term culture or for promoting maturation) TIMING 10-
- 10 **80 d**
- 11 i. Coat a 12-well culture insert with LN511E8 at 0.25-0.5  $\mu$ g/cm<sup>2</sup> and incubate at 37°C for 60
- 12 min.
- 13 ii. Seed FACS-sorted SSEA-4<sup>+</sup>/ITGB4<sup>+</sup>/TRA-1-60<sup>-</sup> cells (i.e. human iCECs) on the 12-well
- 14 culture inserts at  $0.4-1.5 \times 10^5$  cells/well in CEM.
- 15 iii. Incubate the cell culture inserts at 37°C in 5% CO<sub>2</sub> for 5-12 days until cells reach 100%
- 16 confluence. The medium should be changed every two-to-three days. For longer-term culture,
- 17 maintain human iCECs on cell culture inserts up to 10 weeks in CEM changing the medium
- 18 every two-to-three days.

1	v. To promote the maturation of the confluent cells, change the medium to CMM approximately
2	one week before the culture is completed. Although CMM culture promotes maturation, it is not
3	essential for stratification.
4	
5	Timing
6	The entire protocol from the initial preparation of human iPS cells to the fabrication of corneal
7	epithelial cell sheets can take a total of 102 days minimum, but most often, we find that 120+
8	days is required.
9	Steps 1-4, Human iPS cell maintenance and subculture: Plate coating: 3 h
10	Steps 5-14, Human iPS cell maintenance and subculture: Human iPS cell seeding from frozen
11	cell stock: 7 d
12	Steps 15-26, Human iPS cell maintenance and subculture: Cell passaging: at least 7-21 d
13	Steps 27-32, Differentiation culture: Preparing human iPS cells for differentiation culture: 10 d
14	Steps 33-34, Differentiation culture: Ocular cell differentiation culture (Day 0-): 4 w
15	Steps 35-36, Differentiation culture: CDM culture (Day 28-): 4 w
16	Steps 37-39, Differentiation culture: Manual pipetting to remove non-epithelial cells (Day 49): 1
17	d
18	Steps 40-41, Differentiation culture: CEM culture (Day 56-): at least 2-8 w

1	Steps 42-51.	FACS for isolating	corneal epithelial	stem/progenitor	cells (Dav 70-):	: Cell staining
			· · · · · · · · · · · · · · · · · · ·	r o o		

- 2 with antibodies: at least 3 h
- 3 Steps 52-58, FACS for isolating corneal epithelial stem/progenitor cells: Cell sorting: at least

4 2.5 h

- 5 Step 59 Option A, Fabrication of human iCEC sheet: Cultivation on a temperature-responsive
- 6 culture plate and cell harvest: 10-22 d
- 7 Step 59 Option B, Fabrication of human iCEC sheet: Insert culture (for longer-term culture or
- 8 for promoting maturation): 10-80 d
- 9 BOX1, Recommended method for the characterization of cells in a SEAM: 2-7 d
- 10 BOX2, Recommended method for validation of human iPS cell-derived corneal epithelial cell
- 11 sheets: 2-6 d
- 12 See Table 2 for Troubleshooting guidance.
- 13

#### 14 Anticipated Results

- 15 Multi-zonal colony (SEAM) formation By four weeks of differentiation, colonies with
- 16 concentric multi-cellular zones (typically 3-4 zones as shown in Fig. 3A) will have generated
- 17 spontaneously. For the validation of ocular surface epithelial induction (in zone 3) PAX6 and
- 18 p63 double-staining is useful (Fig. 3B). When double-positive cells are detected at three-to-four

1	weeks in the peripheral region of the colony and at 10 weeks overall, the method is deemed to
2	have worked successfully.
3	Fabrication of corneal epithelial cell sheets. After the removal of non-epithelial cells from the
4	SEAM by pipetting, those remaining at 12 weeks of differentiation are subjected to FACS (Fig.
5	4A, B). Flow cytometric analysis at this time typically shows that 5-20% of TRA-1-60 negative
6	cells are human iCECs (i.e. SSEA-4+/ITGB4+ cells) (Fig. 4C). The FACS-sorted human iCECs
7	typically exhibit a small cobblestone-like morphology by phase contrast microscopy and when
8	observed by immunostaining after 2 to 3 weeks of culture in CEM and CMM have become
9	stratified into two to four layers. The stratified cell sheets express K12 and PAX6 throughout all
10	cell layers, as well as MUC16 (on the sheet's surface) and p63 (strongly in the basal region)
11	(Fig. 5).
12	BOX1
13	Recommended method for the characterization of cells in a SEAM Timing: 2-7 d
14	1. Fix differentiated human iPS cells after four weeks (or two weeks for neural crest
15	staining) of differentiation culture in 4% (wt/vol) PFA at room temperature. Fix for 20
16	min. For CHX10 and MITF staining, fix cells that had been differentiated by the retinal
17	differentiation protocol (shown in Step 36).
18	2. Wash the cells with Tris-buffered saline (TBS) three times for 10 min.

1	3.	Incubate the cells in TBS containing 5% (vol/vol) normal donkey serum and $0.3\%$
2		(wt/vol) Triton X-100 (blocking buffer) for 1 hr at room temperature for blocking of
3		non-specific binding and cell permeabilization. For the mouse monoclonal PAX6
4		antibody (AD2.35), cell permeabilization should be performed at 4°C for three days.
5	4.	Incubate the cells with each of following primary antibodies; PAX6 (PRB-278P,
6		BioLegend, 1:300), p63 (4A4, Santa Cruz Biotechnology, 1:200), α-Crystallin (SPA-
7		224, Stressgen Biotechnologies, 1:200), TUBB3 (T2200, Sigma-Aldrich, 1:100),
8		SOX10 (N20, Santa Cruz Biotechnology, 1:100), p75 (ME20.4, Advanced Targeting
9		Systems, 1:100), CHX10 (N-18, Santa Cruz Biotechnology, 1:500) and MITF (C5,
10		Exalpha Biologicals, 1:2000) at 4°C overnight or at room temperature for 3 hrs. For the
11		mouse monoclonal PAX6 antibody (AD2.35, Santa Cruz Biotechnology, 1:60), incubate
12		cells at 4°C for 3 days. Dilute antibodies with TBS containing 1% (vol/vol) normal
13		donkey serum and 0.3% (wt/vol) Triton X-100 (dilution buffer).
14	5.	Wash the cells 3 times with TBS for 5 min.
15	6.	Incubate cells with the secondary antibody, which corresponds to the primary antibody.
16		Use a 1:200 diluted with dilution buffer for 1 hr at room temperature in the dark.
17	7.	Wash the cells 3 times with TBS for 5 min.
18	8.	Repeat Steps 3-7 for double immunostaining.

1	9.	Stain cells (for nuclear staining) with Hoechst 33342 for 10 min at room temperature
2		under protection from light.
3	10.	Wash the cells 3 times with TBS for 5 min.
4	11.	Mount the cells with PermaFluor <sup>TM</sup> and observe by fluorescence microscopy.
5	BOX 2	
6	Recom	mended method for validation of human iPS cell-derived corneal epithelial cell
7	sheets '	Timing: 2-6 d
8	1.	Embed human iCEC sheets in OCT compound and store at -80°C.
9	2.	Cut 10 µm-thick cryostat sections.
10	3.	Dry the frozen sections for at least 2 hrs at room temperature.
11	4.	Wash the slides once with TBS. (For p63 staining, the cells should be fixed with cold
12		methanol for 1 hr before washing with TBS).
13	5.	Incubate the slides in blocking buffer for 1 hr at room temperature.
14	6.	Incubate the slide with each of following antibodies; PAX6 (PRB-278P, BioLegend,
15		1:300), p63 (4A4, Santa Cruz Biotechnology, 1:200), K12 (N16, Santa Cruz
16		Biotechnology, 1:200), K3 (AE5, PROGEN Biotechnik, 1:200), MUC1 (M4H2, Abcam,
17		1:200) and MUC16 (OV185:1, Abcam, 1:200) at 4°C overnight or at room temperature
18		for 3 hrs. Antibodies should be diluted with dilution buffer.

1 7. Wash the slides 3 times with TBS for 5 min.

2	8.	Incubate the slides with the secondary antibody, which corresponds to the primary
3		antibody (1:200 diluted with dilution buffer) for 1 hr at room temperature under
4		protection from light.
5	9.	Wash the cells with TBS 3 times at room temperature.
6	10.	Stain with Hoechst 33342 for 10 min at room temperature under protection from light.
7	11.	Wash the cells three times with TBS for 5 min.
8	12.	Mount the cells with PermaFluor <sup>TM</sup> and observe by fluorescence microscopy.

9

Table 1: Antibodies to verify the existence of ocular cell lineages in each zone

Zone	Cell type	Markers	References
1	Neuronal cell	TUBB3 (T2200, Sigma-Aldrich, 1:100)	8), 20)
2 (early period)	Neural crest	p75 (ME20.4, Advanced Targeting Systems, 1:100)/ SOX10 (N20, Santa Cruz Biotechnology, 1:100)	8), 24)
2 (inner side)	Neuro retinal cell	CHX10 (N-18, Santa Cruz Biotechnology, 1:500)	8), 23)
2 (outer side)	Retinal pigment epithelial cell	MITF (C5, Exalpha Biologicals, 1:2000)	8), 23)
2-3	Lens cell	PAX6 (AD2.35, Santa Cruz Biotechnology, 1:60)/ α-Χρψσιταλλιν (SPA-224, Stressgen Biotechnologies, 1:200)	25), 26)
3	Ocular surface epithelial cell	PAX6 (PRB-278P, BioLegend, 1:300)/ p63 (4A4, Santa Cruz Biotechnology, 1:200)	8), 18), 19)
4	Epithelial cell	p63 (4A4, Santa Cruz Biotechnology, 1:200)	21), 22)

# Table 2. Troubleshooting Table

Step	Problem	Possible reason	Solution
Step 14	Human iPS cells are not	1) Cells are	To verify whether or not human iPS cells have
and 26	in a good condition or in	differentiated	maintained an undifferentiated status, examine
	an unstable condition.		the expression of pluripotent stem cell markers,
			TRA-1-60 and SSEA-4 by immunostaining. If
			cells have differentiated, restarting the iPS cell
			culture is recommended.
		2) The duration of Y-	Incubate human iPS cells in Y-27632-
		27632 treatment is	containing StemFit <sup>™</sup> medium for 24 to 30 hr
		too short or too long.	after cell seeding. An appropriate period of Y-
			27632 treatment is essential for the survival of
			human iPS cells during cell passages.
Step 26	The colony forming	1) LN511E8-coating	Do not allow the surface of the culture plates to
	efficiency (CFE) of	on culture plates is	dry at steps 3 and 15. Add StemFit™ medium
	human iPS cells at cell	insufficient	immediately after the removal of the coating
	passaging is too low or		solution.
	too high. (N.B. The CFE	2) Human iPS cells	Keep the treatment time with the dissociation
	of the 201B7 human iPS	are damaged by	solution brief at around 4-5 min, and gently
	cell line is around 6-14%	enzymatic treatment	harvest human iPS cells using the Cell Scraper
	in our experiments). If a	or mechanical	at cell passaging.
	satisfactory outcome is	harvesting at cell	
	not achieved, it is likely	passaging	
	to reflect changes in cell	3) The duration of Y-	Incubate human iPS cells in Y-27632-
	characteristics during	27632 treatment is	containing StemFit <sup>™</sup> medium for 24 hr to 30 hr
	passaging. If	too short or too long.	after cell seeding. An appropriate treatment with
	subsequent SEAM		Y-27632 is essential to ensure survival of
	formation and corneal		human iPS cells during passaging.
	epithelial cell expansion		
	is not achieved,		
	restarting the iPS cell		
	culture is recommended.		

Step 34	Cells do not generate zone 3, nor a typical SEAM structure by 4 weeks of differentiation culture.	<ol> <li>The cell density is not appropriate.</li> <li>The human iPS cell clone might not be appropriate for conditions in the protocol we describe here.</li> </ol>	Seed human iPS cells at several cell densities ranging from 1500 to 6000 cells/well (6-well plate) or 500 to 2000 cells/well (12-well plate) because the seeding density has a significant influence over the formation of a SEAM and the induction of zone 3. When the seeding density is high, immunostaining for PAX6 and p63 is useful to detect zone 3 because it can become difficult to identify by microscopy alone. The best results were achieved with clone 201B7, and the protocol might need optimization for other clones.
Step 51	The yield of cells after antibody staining is low.	Cells might have been lost in collection tubes during antibody staining.	Use low absorbing tubes (StemFull <sup>TM</sup> ) and serum containing medium, CMM. This is recommended to prevent cell absorption to tubes during incubation with antibodies.
Step 55	The ratio of the corneal epithelial cell fraction is low (i.e. around 5% or lower) based on FACS analysis. In this case, restarting the differentiation culture is strongly recommended, although possible explanations and solutions are indicated here.	<ol> <li>The culture period is too short.</li> <li>Manual pipetting of cells outside SEAM zone 3 is not sufficient.</li> </ol>	Prolong the culture period to 12 weeks. In some cases, even 10 weeks is too brief to obtain a sufficient amount of human iCECs. Perform manual pipetting carefully to remove the non-epithelial like cells that reside in zone 1 and 2 of the SEAM. Even though manual pipetting is not essential to obtain human iCECs, it greatly improves the efficiency of the final corneal epithelial-like cell yield.
Step 56	The yield of sorted human iCECs is low after FACS.	Sorted human iCECs might have been lost in collection tubes.	Use low absorbing tubes (StemFull <sup>™</sup> ) and serum containing medium, CMM. This is recommended to prevent cell absorption to tubes.

Step 59	Human iCECs do not	1) There is a low cell	Seed human iCECs at an appropriate cell
	form epithelial cell	density at human	density as described in step 59. A low seeding
	sheets.	iCEC seeding.	density tends to promote EMT (epithelial-to-
			mesenchymal transition) or the proliferation of
			cells without corneal epithelial characteristics.
			When sufficient numbers of human iCECs, as
			shown in step 59, are not collected after FACS,
			we recommend redoing the FACS.
		2) The human iCEC	Change CEM to CMM before reaching 70-80%
		shrinks after reaching	confluence.
		confluence in CEM.	
		3) The culture period	To ensure that human iCECs become fully
		is too short.	stratified they should be cultivated, first in CEM
			and then CMM, for at least 14 days combined
			time.

1	Figure	legends
---	--------	---------

#### 2 Figure 1

3 Schematic illustration outlining the reconstruction of corneal epithelial tissue from human

#### 4 **iPS cells via SEAM formation**

- 5 PART I: Induction of a SEAM containing various ocular cell anlages (Steps 1-34), indicating
- 6 human iPS cell maintenance culture, preparation for differentiation culture, and the induction of
- 7 multiple ocular cell lineages that form the SEAM.
- 8 PART II: Isolation of corneal epithelial stem/progenitor cells from a SEAM and the steps
- 9 required to reconstruct corneal epithelial tissue *in vitro* (Steps 35-59). This includes corneal
- 10 epithelial cell differentiation and isolation, and the generation of corneal epithelial cell sheets
- 11 using SEAM-derived corneal epithelial stem/progenitor cells.

12

#### 13 **Figure 2**

#### 14 The protocol for SEAM formation and fabrication of corneal epithelial cell sheets.

- 15 Human iPS cells should be passaged three to four times in StemFit<sup>TM</sup> medium on an LN511E8-
- 16 coated dish. Differentiation culture for inducing SEAM formation should then be initiated by
- 17 changing the medium to DM. Corneal epithelial cells can be further induced by changing the
- 18 medium to CDM (at four weeks) and then to CEM (at eight weeks); these contain KGF and Y-

1	27632 for promoting corneal differentiation. After CEM culture at around 12 weeks of
2	differentiation, the corneal epithelial cells, including stem/progenitor cells, can be isolated by
3	FACS and cultivated again in CEM and then CMM to develop corneal epithelial tissue. DM:
4	Differentiation medium, CDM: Corneal differentiation medium, CEM: Corneal epithelial
5	maintenance medium, CMM: Corneal epithelium maturation medium.
6	
7	Figure 3
8	Characterization of cells in a SEAM
9	(A) Phase-contrast images for undifferentiated human iPS cell colonies and a SEAM after four
10	and six weeks of differentiation culture. Scale bars, 200 $\mu m$ . The macro photo (scale bar, 2 mm)
11	shows several SEAMs, variously sized.
12	(B) Characterization of cells in a SEAM by immunostaining for ocular cell-related markers:
13	PAX6 (PRB-278P, BioLegend, 1:300, green) and p63 (4A4, Santa Cruz Biotechnology, 1:200,
14	red) indicate corneal epithelial cells at four weeks of differentiation; PAX6 (AD2.35, Santa Cruz
15	Biotechnology, 1:60, green) and $\alpha$ -crystallin (SPA-224, Stressgen Biotechnologies, 1:200, red)
16	indicate lens cells at four weeks of differentiation); TUBB3 (T2200, Sigma-Aldrich, 1:100,
17	green) and p63 (4A4, Santa Cruz Biotechnology, 1:200, red) indicate neuronal/epithelial cells at
18	four weeks of differentiation); p75 (ME20.4, Advanced Targeting Systems, 1:100, green) and

1	SOX10 (N20, Santa Cruz Biotechnology, 1:100, red) indicate neural crest cells at two weeks of
2	differentiation); MITF (C5, Exalpha Biologicals, 1:2000, green) and CHX10 (N-18, Santa Cruz
3	Biotechnology, 1:500, red) indicate retinal cells at seven weeks of differentiation using the
4	protocol for retinal differentiation. CRYA: $\alpha$ -crystallin, Nuclei, Blue. Scale bars, 100 $\mu$ m.
5	
6	Figure 4
7	Isolation of corneal epithelial cells from a SEAM
8	(A) Enrichment of corneal epithelial-type cells from zone 3 of the SEAM by manual pipetting at
9	seven weeks of differentiation. Scale bars, 200 µm.
10	(B) A 12-week differentiated SEAM-derived cells that underwent pipetting. Scale bars, 200 $\mu$ m.
11	(C) Isolation of corneal epithelial cells by FACS using anti-TRA-1-60, SSEA-4 and ITGB4
12	antibodies from 14-week differentiated human iPS cells (upper graphs). In the TRA-1-60
13	negative cell population, 12% of the cells are corneal epithelial cells defined as SSEA-
14	4 <sup>+</sup> /ITGB4 <sup>+</sup> cells (range typically 5-20%). The results for the cells stained with isotype control
15	antibodies are shown in lower graphs indicating almost no cells (<0.1%) in the SSEA-
16	4 <sup>+</sup> /ITGB4 <sup>+</sup> region.
17	

**Figure 5** 

## 1 Fabrication of a corneal epithelial cell sheet

2	Immu	nostaining of human SEAM-derived cell sheets (upper panels; 23 days: lower panels; 76
3	days	of cultivation on cell culture inserts after FACS) for corneal epithelial-related markers,
4	PAXe	5 (PRB-278P, BioLegend, 1:300), p63 (4A4, Santa Cruz Biotechnology, 1:200), K12 (N16,
5	Santa	Cruz Biotechnology, 1:200), K3 (AE5, PROGEN Biotechnik, 1:200), MUC1 (M4H2,
6	Abca	m, 1:200) and MUC16 (OV185:1, Abcam, 1:200). Nuclei stain red. Scale bars, 50 $\mu$ m.
7		
8	Refei	rences
9	1	Ikeda, H. <i>et al.</i> Generation of Rx+/Pax6+ neural retinal precursors from embryonic
10		stem cells. Proc Natl Acad Sci USA 102, 11331-11336,
11		doi:10.1073/pnas.0500010102 (2005).
12	2	Kawasaki, H. et al. Generation of dopaminergic neurons and pigmented epithelia
13		from primate ES cells by stromal cell-derived inducing activity. Proc Natl Acad Sci
14		USA <b>99</b> , 1580-1585, doi:10.1073/pnas.032662199 (2002).
15	3	Eiraku, M. et al. Self-organizing optic-cup morphogenesis in three-dimensional
16		culture. <i>Nature</i> <b>472</b> , 51-56, doi:10.1038/nature09941 (2011).
17	4	Nakano, T. et al. Self-formation of optic cups and storable stratified neural retina
18		from human ESCs. Cell Stem Cell 10, 771-785, doi:10.1016/j.stem.2012.05.009
19		(2012).
20	<b>5</b>	Zhong, X. et al. Generation of three-dimensional retinal tissue with functional
21		photoreceptors from human iPSCs. <i>Nature communications</i> <b>5</b> (2014).
22	6	Reichman, S. et al. From confluent human iPS cells to self-forming neural retina
23		and retinal pigmented epithelium. Proc Natl Acad Sci USA 111, 8518-8523,
24		doi:10.1073/pnas.1324212111 (2014).
25	7	Mellough, C. B. et al. IGF - 1 Signaling Plays an Important Role in the Formation
26		of Three - Dimensional Laminated Neural Retina and Other Ocular Structures
27		from Human Embryonic Stem Cells. STEM CELLS (2015).
28	8	Hayashi, R. et al. Co-ordinated ocular development from human iPS cells and
29		recovery of corneal function. <i>Nature</i> <b>531</b> , 376-380 (2016).

1	9	Hayashi, R. et al. Generation of corneal epithelial cells from induced pluripotent
2		stem cells derived from human dermal fibroblast and corneal limbal epithelium.
3		<i>PLoS One</i> <b>7</b> , e45435, doi:10.1371/journal.pone.0045435 (2012).
4	10	Shalom - Feuerstein, R. et al. Pluripotent Stem Cell Model Reveals Essential Roles
5		for miR - $450b$ - $5p$ and miR - $184$ in Embryonic Corneal Lineage Specification.
6		Stem Cells <b>30</b> , 898-909 (2012).
7	11	Bock, C. et al. Reference Maps of human ES and iPS cell variation enable high-
8		throughput characterization of pluripotent cell lines. Cell 144, 439-452 (2011).
9	12	Nasu, A. et al. Genetically matched human iPS cells reveal that propensity for
10		cartilage and bone differentiation differs with clones, not cell type of origin. $P\!LoS$
11		<i>One</i> <b>8</b> , e53771 (2013).
12	13	Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467,
13		285-290 (2010).
14	14	Takahashi, K. et al. Induction of pluripotent stem cells from adult human
15		fibroblasts by defined factors. Cell 131, 861-872, doi:10.1016/j.cell.2007.11.019
16		(2007).
17	15	Nakagawa, M. et al. A novel efficient feeder-free culture system for the derivation of
18		human induced pluripotent stem cells. Scientific reports 4 (2014).
19	16	Kajiwara, M. et al. Donor-dependent variations in hepatic differentiation from
20		human-induced pluripotent stem cells. Proceedings of the National Academy of
21		<i>Sciences</i> <b>109</b> , 12538-12543 (2012).
22	17	Miyazaki, T. et al. Laminin E8 fragments support efficient adhesion and expansion
23		of dissociated human pluripotent stem cells. <i>Nature communications</i> <b>3</b> , 1236 (2012).
24	18	Collinson, J. M., Quinn, J. C., Hill, R. E. & West, J. D. The roles of Pax6 in the
25		cornea, retina, and olfactory epithelium of the developing mouse embryo. <i>Dev Biol</i>
26		<b>255</b> , 303-312 (2003).
27	19	Ouyang, H. et al. WNT7A and PAX6 define corneal epithelium homeostasis and
28		pathogenesis. <i>Nature</i> <b>511</b> , 358-361, doi:10.1038/nature13465 (2014).
29	20	Pang, Z. P. et al. Induction of human neuronal cells by defined transcription factors.
30		Nature <b>476</b> , 220-223 (2011).
31	21	Yang, A. et al. p63 is essential for regenerative proliferation in limb, craniofacial
32		and epithelial development. Nature 398, 714-718 (1999).
33	22	Senoo, M., Pinto, F., Crum, C. P. & McKeon, F. p63 Is essential for the proliferative
34		potential of stem cells in stratified epithelia. Cell 129, 523-536,
35		doi:10.1016/j.cell.2007.02.045 (2007).
36	23	Meyer, J. S. et al. Modeling early retinal development with human embryonic and

1		induced pluripotent stem cells. Proceedings of the National Academy of Sciences
2		<b>106</b> , 16698-16703 (2009).
3	24	Kim, J., Lo, L., Dormand, E. & Anderson, D. J. SOX10 maintains multipotency and
4		inhibits neuronal differentiation of neural crest stem cells. Neuron 38, 17-31 (2003).
<b>5</b>	25	Ooto, S. Induction of the Differentiation of Lentoids from Primate Embryonic Stem
6		Cells. Investigative Ophthalmology & Visual Science 44, 2689-2693,
7		doi:10.1167/iovs.02-1168 (2003).
8	26	Cvekl, A., Yang, Y., Chauhan, B. K. & Cveklova, K. Regulation of gene expression by
9		Pax6 in ocular cells: a case of tissue-preferred expression of crystallins in lens. <i>The</i>
10		International journal of developmental biology 48, 829 (2004).
11	27	Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts.
12		science <b>282</b> , 1145-1147 (1998).
13	28	Stepp, M. A., Spurr-Michaud, S., Tisdale, A., Elwell, J. & Gipson, I. K. Alpha 6 beta
14		4 integrin heterodimer is a component of hemidesmosomes. Proceedings of the
15		National Academy of Sciences 87, 8970-8974 (1990).
16	29	Dowling, J., Yu, QC. & Fuchs, E. Beta4 integrin is required for hemidesmosome
17		formation, cell adhesion and cell survival. <i>The Journal of cell biology</i> <b>134</b> , 559-572
18		(1996).
19	30	Truong, T. T., Huynh, K., Nakatsu, M. N. & Deng, S. X. SSEA4 is a potential
20		negative marker for the enrichment of human corneal epithelial stem/progenitor
21		cells. Invest Ophthalmol Vis Sci 52, 6315-6320, doi:10.1167/iovs.11-7518 (2011).
22	31	Nishida, K. et al. Corneal reconstruction with tissue-engineered cell sheets
23		composed of autologous oral mucosal epithelium. N Engl J Med <b>351</b> , 1187-1196,
24		doi:10.1056/NEJMoa040455 (2004).
25	32	Kawasaki, H. et al. Induction of midbrain dopaminergic neurons from ES cells by
26		stromal cell-derived inducing activity. Neuron 28, 31-40 (2000).
27	33	Nishida, K. et al. Functional bioengineered corneal epithelial sheet grafts from
28		corneal stem cells expanded ex vivo on a temperature-responsive cell culture
29		surface. Transplantation 77, 379-385, doi:10.1097/01.TP.0000110320.45678.30
30		(2004).
31		
32		
04		
33		

# 1 Acknowledgements

2	We thank Y. Kobayashi for technical assistance. This work was supported in part by the Project
3	for the Realization of Regenerative Medicine of the Japan Agency for Medical Research and
4	Development (AMED), and the Japan Science and Technology Agency (JST), as well as by a
5	Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science
6	and Technology of Japan.
7	
8	Author contributions
9	R.H., and K.N. designed the research; R.H., Y.I., R.K., and H.T. performed the experiments on
10	human iPS cells differentiation culture and acquired the data; Y.T. performed the experiments on
11	human iPS cell maintenance in culture and acquired the data; Y.I and R.K performed the cell
12	sorting experiments and acquired the data; R.H., Y.I., R.K., Y.T. and H.T. analyzed the data and
13	provided technical assistance to the protocol; Y.S., M.T. and A.J.Q supervised the project and
14	provided critical advice; K.S. provided reagents (LN511E8); and R.H. and A.J.Q wrote the
15	manuscript.
16	
17	Competing financial interests

18 The authors declare that they have no competing financial interests.